bannerHON
img
HONnews
HONnews
img PATIENT / PARTICULIER img PROFESSIONNEL DE SANTE img WEBMESTRE img
img
 
img
HONcode sites
Khresmoi - new !
HONselect
News
Conferences
Images

Themes:
A B C D E F G H I
J K L M N O P Q
R S T U V W X Y Z
Browse archive:
2014: D N O S A J J M A M F J
2013: D

 
  Other news for:
Breast Neoplasms
Neoplasms
Drug Therapy
Menopause
Postmenopause
 Resources from HONselect
Drug May Lower Odds of Early Menopause in Breast Cancer Patients
When added to chemotherapy, it also boosted survival rates, researchers report

By Robert Preidt

FRIDAY, May 30, 2014 (HealthDay News) -- Adding a drug called goserelin to chemotherapy reduces the risk of early menopause in breast cancer patients and seems to improve survival, according to a new study.

Early menopause is one of the most upsetting side effects of chemotherapy among young breast cancer patients, the researchers noted.

The investigators found that adding goserelin to chemotherapy significantly reduced the risk of early menopause in breast cancer patients, and increased the chances that survivors could get pregnant and have a healthy baby later.

Goserelin (Zoladex) temporarily puts the ovaries "at rest" during chemotherapy, according to study senior author Dr. Kathy Albain, of Loyola University Medical Center in Maywood, Ill.

"We found that, in addition to reducing the risk of early menopause, and all of the symptoms that go along with menopause, goserelin was very safe and may even improve survival," she said in a Loyola news release. "I think these findings are going to change our clinical practice."

The study included 257 premenopausal women younger than 50 with early stage estrogen- or progesterone-receptor-negative breast cancers. The patients were randomly assigned to receive either standard chemotherapy or chemotherapy plus goserelin.

After two years, 45 percent of women in the chemotherapy-only group showed signs of early menopause, compared with just 20 percent of those in the chemo plus goserelin group. In addition, the authors noted, the pregnancy rate was 11 percent in the chemotherapy-only group and 21 percent in the goserelin group.

After four years, 89 percent of the women in the chemo plus goserelin group showed no signs or symptoms of cancer, compared with 78 percent of those in the chemotherapy-only group. Survival rates at four years were 92 percent in the goserelin group and 82 percent in the chemotherapy-only group, according to the report.

"Premenopausal women beginning chemotherapy for early breast cancer should consider this new option to prevent premature ovarian failure," the study authors concluded.

The findings are scheduled for presentation Saturday at the annual meeting of the American Society of Clinical Oncology (ASCO), held in Chicago. Research presented at meetings is considered preliminary until published in a peer-reviewed medical journal.

Goserelin is an injection drug that is similar to a natural hormone made by the body. It is approved by the U.S. Food and Drug Administration for treatment of prostate cancer, certain benign gynecological conditions and certain breast cancers.

More information

The U.S. National Library of Medicine has more about breast cancer.

SOURCE: Loyola University, news release, May 30, 2014

Copyright © 2014 HealthDay. All rights reserved. URL:http://consumer.healthday.com/Article.asp?AID=688252

Resources from HONselect: HONselect is the HON's medical search engine. It retrieves scientific articles, images, conferences and web sites on the selected subject.
Neoplasms
Breast
Breast Neoplasms
Drug Therapy
Women
Research Personnel
Risk
Survival Rate
Prostatic Neoplasms
The list of medical terms above are retrieved automatically from the article.

Disclaimer: The text presented on this page is not a substitute for professional medical advice. It is for your information only and may not represent your true individual medical situation. Do not hesitate to consult your healthcare provider if you have any questions or concerns. Do not use this information to diagnose or treat a health problem or disease without consulting a qualified healthcare professional.
Be advised that HealthDay articles are derived from various sources and may not reflect your own country regulations. The Health On the Net Foundation does not endorse opinions, products, or services that may appear in HealthDay articles.


Home img About us img MediaCorner img HON newsletter img Site map img Ethical policies img Contact